Lorpotem XL 50 Tablet contains Metoprolol Succinate 47.5 mg, a cardioselective beta-1 adrenergic receptor blocker used primarily in the management of hypertension, angina pectoris, and heart failure. By selectively inhibiting beta-1 receptors in the heart, Lorpotem XL reduces heart rate, myocardial contractility, and cardiac output, thereby decreasing oxygen demand and lowering blood pressure. This extended-release formulation ensures a sustained therapeutic effect, allowing once-daily dosing and improved patient compliance. Lorpotem XL is indicated for the treatment of essential hypertension to reduce the risk of cardiovascular events, management of stable angina to prevent anginal attacks, and as part of the therapeutic regimen in chronic heart failure to improve survival and reduce hospitalizations. It is also used post-myocardial infarction to reduce mortality and prevent recurrent cardiac events. The medication should be used cautiously in patients with bradycardia, heart block, or severe peripheral arterial disease. Common adverse effects include fatigue, dizziness, and gastrointestinal disturbances. Dose adjustments may be necessary in hepatic impairment. Lorpotem XL should be administered under medical supervision, with gradual dose titration and careful monitoring of heart rate and blood pressure to optimize therapeutic outcomes and minimize risks.